Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James L Howard

Showing results (141-150 of 143) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 143 results.
The Journal of Bone and Joint Surgery. American Volume|June 22, 2012
Comparative long-term survivorship of uncemented acetabular components in revision total hip arthroplastyHilal Maradit Kremers, James L Howard, Youlonda Loechler, et al.
The Journal of Bone and Joint Surgery. American Volume|September 15, 2011
Comparative survival of uncemented acetabular components following primary total hip arthroplastyJames L Howard, Hilal Maradit Kremers, Youlonda A Loechler, et al.
Molecular Pharmaceutics|March 2, 2017
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsJohn S Schardt, Jinan M Oubaid, Sonya C Williams, et al.
Pageof 15

Showing results (141-150 of 143) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 143 results.
The Journal of Bone and Joint Surgery. American Volume|June 22, 2012
Comparative long-term survivorship of uncemented acetabular components in revision total hip arthroplastyHilal Maradit Kremers, James L Howard, Youlonda Loechler, et al.
The Journal of Bone and Joint Surgery. American Volume|September 15, 2011
Comparative survival of uncemented acetabular components following primary total hip arthroplastyJames L Howard, Hilal Maradit Kremers, Youlonda A Loechler, et al.
Molecular Pharmaceutics|March 2, 2017
Engineered Multivalency Enhances Affibody-Based HER3 Inhibition and Downregulation in Cancer CellsJohn S Schardt, Jinan M Oubaid, Sonya C Williams, et al.
Pageof 15